|
시장보고서
상품코드
2039001
CAR T 세포 치료 시장 : 표적 항원별, 치료 용도별, 치료법별, 최종사용자별, 지역별CAR T-cell Therapy Market, By Targeted Antigen, By Therapeutic Application, By Therapy Type, By End User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
CAR T 세포 치료 시장은 2026년에 48억 3,000만 달러로 추정되며, 2033년까지 184억 6,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 21.1%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 48억 3,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 21.10% | 2033년 시장 규모 예측: | 184억 6,000만 달러 |
키메라 항원 수용체(CAR) T 세포 치료는 면역 T 세포를 이용해 암을 파괴하는 면역치료의 일종입니다. CAR T 세포 치료는 T 세포의 유전자 변형을 수반하기 때문에 세포 기반 유전자 치료라고도 불립니다. 키메라 항원 수용체(CAR) T 세포 치료는 백혈구 분리법이라는 절차를 통해 인체에서 T 세포를 채취합니다. 이후 채취한 T 세포에 특정 키메라 항원 수용체(CAR) 유전자를 도입하여 변형시킨 후 CAR-T 세포라고 부릅니다. 변형 후 세포를 증식시킨 후 인체에 투여합니다. 특정 유형의 암과 싸우기 위해 다양한 유형의 CAR T 세포 치료법이 개발되고 있습니다. CAR-T 세포는 환자별로 맞춤화된 후 혈액에 주입됩니다. CAR T 세포 치료는 암을 치료하기 위한 새로운 유전자 치료법으로 활용되고 있습니다. 특정 암에 대한 다양한 CAR T 세포 치료제의 안전성과 유효성을 검증하기 위해 현재 다양한 임상 및 전임상시험이 진행되고 있습니다. 또한, 미국 질병예방통제센터(CDC)의 암 인식 개선 캠페인 등 여러 정부에서 암에 대한 인식을 개선하기 위한 노력을 기울이고 있습니다.
시장 역학
시장 내 주요 기업들의 제품 승인과 같은 유기적 전략의 채택 확대가 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 5월 세계 헬스케어 기업 중 하나인 노바티스 AG는 재발성 또는 난치성 여포성 림프종 성인 환자 치료를 위한 CAR T 세포 치료제 '킴리아(tisagenlecleucel)'에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 이번 승인은 68%의 환자에게서 반응을 보인 임상 2상 시험 결과를 바탕으로 이루어졌습니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계 CAR T 세포 치료 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계 CAR T 세포 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 CAR T 세포 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 CAR T 세포 치료 시장 : 표적 항원별, 2021-2033년
제5장 세계의 CAR T 세포 치료 시장 : 치료 용도별, 2021-2033년
제6장 세계의 CAR T 세포 치료 시장 : 치료법별, 2021-2033년
제7장 세계의 CAR T 세포 치료 시장 : 최종사용자별, 2021-2033년
제8장 세계의 CAR T 세포 치료 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 추천
제11장 참고문헌 및 조사 방법
KSM 26.06.04CAR T-cell Therapy Market is estimated to be valued at USD 4.83 Bn in 2026 and is expected to reach USD 18.46 Bn by 2033, growing at a compound annual growth rate (CAGR) of 21.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.83 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 21.10% | 2033 Value Projection: | USD 18.46 Bn |
Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).
Market Dynamics
Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global CAR T cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market.
Market Segmentation
- Global CAR T Cell Therapy Market, By Targeted Antigen
- CD19
- BCMA
- HER2
- GD2
- CD20
- CD22
- CD30
- CD33
- HER1
- Others (CLDN18, etc.)
- Global CAR T Cell Therapy Market, By Therapeutic Application
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others (Gastric Cancer, etc.)
- Global CAR T Cell Therapy Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- CARsgenTherapeutics Co., Ltd.
- Aurora Biopharma
- Legend Biotech
- Gilead Sciences, Inc.
- Pfizer Inc.
- bluebird bio, Inc.
- Sorrento Therapeutics, Inc.
- Mustang Bio
- Fate Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global CAR T-cell Therapy Market, By Targeted Antigen
- Global CAR T-cell Therapy Market, By Therapeutic Application
- Global CAR T-cell Therapy Market, By Therapy Type
- Global CAR T-cell Therapy Market, By End User
- Global CAR T-cell Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global CAR T-cell Therapy Market, By Targeted Antigen, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- CD19
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- BCMA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- HER2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- GD2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CD20
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CD22
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CD30
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CD33
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- HER1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global CAR T-cell Therapy Market, By Therapeutic Application, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hematological Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Solid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global CAR T-cell Therapy Market, By Therapy Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Autologous CAR T-cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Allogeneic CAR T-cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global CAR T-cell Therapy Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global CAR T-cell Therapy Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Legend Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- bluebird bio, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CARsgen Therapeutics Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mustang Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sorrento Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
